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1. Introduction 
Pain, as a sub modality of somatic sensation, has been defined as a complex constellation of 
unpleasant sensory, emotional and cognitive experiences provoked by real or perceived 
tissue damage and manifested by certain autonomic, psychological, and behavioral 
reactions. The benefit of these unpleasant sensations, however, is underscored by extreme 
cases: patients lacking the ability to perceive pain due to hereditary neuropathies often 
maintain unrealized infections; self mutilate, and have curtailed life spans. Normally, 
nociception and the perception of pain are evoked only at pressures and temperatures 
extreme enough to potentially injured tissues and by toxic molecules and inflammatory 
mediators. As opposed to the relatively more objective nature of other senses, pain is highly 
individual and subjective and the translation of nociception into pain perception can be 
curtailed by stress or exacerbated by anticipation (Woolf). 
Chronic pain is estimated to affect millions of people worldwide and is one of the most 
common reasons for physician visits (Scascighini et al. 2008). Inflammation may cause direct 
painful stimuli as well as sensitize nociceptors to stimulation (McMahon et al. 2005). Thus, 
there are multiple points along the pain pathway that represent opportunities for 
therapeutic intervention. Despite this, there are only a limited number of mechanisms 
through which current pain medications work. Major classes of analgesics include opioids, 
non-steroidal anti-inflammatory drugs, antidepressants, and anticonvulsants. Although 
these treatments provide relief, the effects are often incomplete and complicated by serious 
side effects and/or tolerance. Thus, therapeutics with novel mechanisms of actions are 
desperately needed (Finnerup et al. 2005).  
What exactly, from a neurobiological perspective, is pain? Pain is actually three quite 
different things, although it is difficult to make the distinction; nociceptive pain, 
inflammatory pain and neuropathic pain. Nociceptive pain is not a clinical problem, except 
in the specific context of surgery and other clinical procedures that necessarily involve 
noxious stimuli, where it must be suppressed by local and general anesthetics or high-dose 
opioids (Woolf). 
Nociception involves multiple steps from the peripheral receptor, the afferent nerve 
transmitting the impulse to the spinal cord, the signal processing in the dorsal horn, with 
inhibitory and facilitatory elements and finally transmission to higher cerebral centers 
where the peripheral nociceptive stimulus is perceived as pain (Arendt-Nielsen and 
Sumikura 2002).   
The second kind of pain is also adaptive and protective. By heightening sensory sensitivity 
after unavoidable tissue damage, this pain assists in the healing of the injured body part by 
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creating a situation that discourages physical contact and movement. Pain hypersensitivity, 
or tenderness, reduces further risk of damage and promotes recovery, as after a surgical 
wound or in an inflamed joint, where normally innocuous stimuli now elicit pain. This pain 
is caused by activation of the immune system by tissue injury or infection, and is therefore 
called inflammatory pain. 
Finally, there is the pain that is not protective, but maladaptive, resulting from abnormal 
functioning of the nervous system. This pathological pain, which is not a symptom of some 
disorder but rather a disease state of the nervous system, can occur after damage to the 
nervous system (neuropathic pain), but also in conditions in which there is no such damage 
or inflammation (dysfunctional pain) (Woolf).  
The incidence of pain rises as people get older and women are more likely to be in pain than 
men. Pain management strategies include pain relieving medications, physical or 
occupational therapy and complementary therapies (such as acupuncture and massage). 
Pharmacologic therapies are the foundation of chronic pain management. These therapies 
include nonopioids, opioids, and adjuvant analgesics, physical techniques physical 
measures, such as physical activity, physical and occupational therapy, orthotics, and 
assistive devices can serve as adjuncts to analgesics in the management of chronic pain 
(Paice and Ferrell).   
On the other hand in recent years, we and others have focused on the relationship between 
neuroprotection and pain mechanism and management. Thus in this chapter we will review 
recent progress related to neuronal mechanism for using neuroprotective agents alone or in 
combination with antinociceptive drugs to reduce the pain. In addition we will focus on the 
effect of neuroprotective agents on prevention of tolerance to the analgesic effect of opiates. 
2. Neuroprotection 
Neuroprotection is the mechanism and strategies used to protect against neural injury or 
degeneration in the central nervous system (CNS). There is a wide range of neuroprotective 
products available or under investigation. Some products with neuroprotective effects are 
grouped into the following categories: 
 Free radical scavengers  
 Anti excitotoxic agents 
 Anti apoptotic agents 
 Anti inflammatory agents 
 Neurotrophic factors 
To better understand, we first discuss the mechanism by which neurotoxins induce toxicity. 
3. Glutamate 
Glutamate is a neurotransmitter with roles such as long-term potentiation and synaptic 
plasticity of the brain (Harris et al. 1984) and is also a exitotoxin whose neurotoxicity has 
been associated with numerous neurodegenerative diseases, such as Alzheimer disease 
(AD), (Kihara et al. 2002) vascular dementia, (Martinez et al. 1993) Parkinson disease 
(Greenamyre 2001) and amyotrophic lateral sclerosis (Cid et al. 2003).  
Glutamatergic synapses are the key excitatory synapses within the brain, and mechanisms 
of both hyperglutamatergic and hypoglutamatergic functioning have been implicated in the 
pathophysiology of CNS disorders (Olney et al. 1999). 
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Glutamatergic receptors include both iontropic and metabotropic receptor subtypes. The 
iontropic receptors include N-Methyl-D-Aspartat (NMDA), ǂ-amino-3-hydroxy-5-methyl-4-
isoxazole propionic acid (AMPA), and kainate receptors. Binding of glutamate to these 
receptors causes Ca2+ and Na+ entry into neurons, resulting in excitatory postsynaptic 
potentials and membrane depolarization. In addition, increased intracellular Ca2+ levels 
activate a number of signaling cascades (Berridge 1998). The NMDA receptor forms a 
channel allowing for ion influx, whereas the AMPA and kainate receptors open voltage-
sensitive ion channels on the cell membrane. The NMDA receptor is voltage-gated and is 
blocked by magnesium and modulated by two coagonists, glycine and d-serine, as well as 
by several intracellular and extracellular mediators (Millan 2005)). It has been proposed that 
NMDA receptor hypofunction may lead to excessive stimulation of other iontropic 
receptors, causing a cascade of excitotoxic events including oxidative stress and apoptosis 
(Deutsch et al. 2001). Dysregulation of glutamateric functioning has been observed across 
many components of the glutamate neurotransmission system.  
The mechanism of glutamate-induced neuronal death has been extensively studied: 
glutamate induces neuronal death via stimulation of NMDA receptor through which Ca2+ 
enters the cell and activates Ca2+-dependent nitric oxide (NO) synthase, resulting in 
excessive nitric oxide formation, production of radicals, mitochondrial dysfunction and 
cell death (Kaneko et al. 1997). It has been shown that glutamate induces neuronal death 
associated with necrosis and apoptosis. Necrosis is caused by catastrophic cell damage 
and is characterized by cell swelling, injury to cytoplasmic organelles and rapid collapse 
of internal homeostasis, leading to the lysis of membranes and the release of cellular 
contents, resulting in inflammation. On the other hand, apoptosis is a process 
characterized by cell shrinkage, membrane blebbing, nuclear pyknosis, chromatin 
condensation and genomic fragmentation (Kerr et al. 1972; Schulte-Hermann et al. 1992; 
Takada-Takatori et al. 2009).  
In rodents, blocking of NMDA receptors is associated with increased release of glutamate 
within the cerebral cortex (Moghaddam et al. 1997), (Adams and Moghaddam 1998) and 
nucleus accumbens (Razoux et al. 2007). However, elevations in glutamate within the 
prefrontal cortex of rodents occurs during short-term administration of NMDA antagonists, 
whereas long-term administration over 7 consecutive days actually results in a trend for 
lower basal levels and lower dialysate levels of glutamate upon challenge (Zuo et al. 2006). 
Thus, excitotoxic events associated with NMDA antagonists may be reflected by initial 
increases in glutamatergic neurotransmission that are followed subsequently and 
chronically by lower levels.  
4. Apoptosis and N-Methyl-D-Aspartate antagonist-induced 
neurodegeneration 
As noted before glutamate can induce apoptosis via NMDA receptor activation. Apoptosis 
or programmed cell death is a process normally associated with the elimination of 
redundant neurons during neurodevelopment (Johnson et al. 1995). Apoptosis involves the 
regulation of a complex molecular cascade controlling the activation of a family of cysteine 
proteases known as caspase proteins (Glantz et al. 2006). Caspases are responsible for 
breaking down important structural and functional proteins, leading to cellular degradation 
and eventually death. Apoptosis results from a cascade of gene activation and involves 
genes that both promote (i.e., Bax) (Schlesinger et al. 1997), (Gross et al. 1998) and oppose 
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the process (i.e., Bcl-2) (Craig 1995), (Schlesinger et al. 1997), (Adams and Cory 1998). In a 
study we showed that there is a relation between glutamate increase and apoptosis 
promotion and increase in proapoptotic agent activity in both cerebral cortex and lumbar 
spinal cord of rat (Hassanzadeh et al.).  
A vast array of stimuli can activate apoptosis in neurons (Sastry and Rao 2000). Many of 
these stimuli have been implicated in the pathophysiology of opioid–induced tolerance 
including glutamate excitotoxicity, increased calcium flux and mitochondria dysfunction 
and these mechanisms are discussed in detail later in this chapter.    
5. Neuroactive steroids are neuroprotective 
Neuroactive steroids are endogenous neuromodulators synthesized either within the brain 
(neurosteroids) or in the periphery by the adrenal glands and gonads. In addition to the 
classic effect of steroids on gene transcription via binding to intracellular steroid receptors, 
neuroactive steroids can alter neuronal excitability via nongenomic effects by acting at 
inhibitory Gama Amino Butiric Acid A (GABAA) receptors and/or excitatory NMDA 
receptors, among others (Shulman and Tibbo 2005), (Marx et al. 2006). There is also evidence 
for a potential role of these neurosteroids in controlling GABA and glutamate release. 
Neuroactive steroids have also been implicated in neuroprotection, myelination, and 
modulation of the stress response. A number of neuroactive steroids are present in human 
postmortem brain at physiologically relevant nanomolar concentrations and serve as 
allosteric modulators of the GABAA receptor (Marx et al. 2006). Neuroactive steroids that are 
effective modulators of GABAA and/or T-type Ca2+ channels are promising tools for 
studying the role of these channels in peripheral pain perception. They appear to be very 
effective in alleviating peripheral Nociception in rat models of acute and chronic pain 
(Jevtovic-Todorovic et al. 2009).  
6. Acetyl Choline Receptors (AChRs) and neuroprotection 
Agonists and antagonist selective for AChR subtypes have been used in experimental and 
clinical research. Some of those compounds are potential candidates for the treatment of 
neurodegenerative disease such as Alzheimer's disease, Parkinson's disease and others. A 
growing list of in vivo and in vitro research suggest that AChRs modulators are gaining 
importance as clinically relevant neuroprotective drugs (Mudo et al. 2007). 
The inhibition of ǂ7 AChRs decreases the GABAergic tone causing increased ACh release 
into the synaptic cleft (Giorgetti et al. 2000), which then activates the ǂ4ǃ2 AChRs located 
post-synaptically. The selective ǂ7 inhibitor methyllycaconitine (Ivy Carroll et al. 2007) 
mimics, at least in part, the neuroprotective effect of 4R (Ferchmin et al. 2003). Other in vivo 
and in vitro studies confirm that ǂ7 inhibition can be neuroprotective (de Fiebre and de 
Fiebre 2005), (Laudenbach et al. 2002), (Martin et al. 2004).  
Protection of neurons from neuronal damage and cell death in neurodegenerative disease is 
a major challenge in neuroscience research. Donepezil, galantamine and tacrine are 
acetylcholinesterase inhibitors used for the treatment of Alzheimer’s disease, and were 
believed to be symptomatic drugs whose therapeutic effects are achieved by slowing the 
hydrolysis of acetylcholine at synaptic termini. However, recent accumulated evidence 
strongly suggests that these acetylcholinesterase inhibitors also possess neuroprotective 
properties whose mechanism is independent of acetylcholinesterase inhibition. It has been 
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shown that acetylcholinesterase inhibitors protect neurons from glutamate-induced 
neurotoxicity in the primary culture of rat cortical neurons.  
The long-standing belief was that acetylcholinesterase inhibitors are symptomatic agents 
that ameliorate cholinergic deficits by slowing the hydrolysis of acetylcholinesterase at 
synaptic nerve termini; however, recent studies have shown that acetylcholinesterase 
inhibitors have other pharmacological properties, for example, neuroprotection against toxic 
insults, such as glutamate and up-regulation of nicotinic receptors (Akaike 2006), (Takada-
Takatori et al. 2009). 
Several reports have indicated that activation of cholinergic neurons in the central nervous 
system produces antinociception and analgesia in a variety of animals, including humans 
(Harte et al. 2004) provide evidence supporting the involvement of the intralaminar 
thalamus in muscarinic induced antinociception. Pharmacological experiments have shown 
that the microinjection of acetylcholine or carbachol into specific brainstem nuclei can 
produce antinociception and can be reversed by muscarinic receptor antagonists (Brodie 
and Proudfit 1984), (Yaksh et al. 1985). Meanwhile some other types of receptors or drugs 
produce analgesia by mediation of ACh. Sumatriptan (5- HT1agonist) is able to induce 
antinociception by increasing cholinergic neurotransmission (Ghelardini et al. 1997). D2 
antagonist prochlorperazine exerts an antinocicptive effect mediated by a central cholinergic 
mechanism (Ghelardini et al. 2004), (Yang et al. 2008). In addition, more recently we showed 
that an acethylcolinesterase inhibitor, donepezil, could prevent tolerance to the analgesic 
effect of morphine (unpublished data).  
7. Cannabinoids, pain and neuroprotection  
Pain severely impairs quality of life. Currently available treatments, generally opioids and 
anti-inflammatory drugs, are not always effective for certain painful conditions. The 
discovery of the cannabinoid receptors in the 1990s led to the characterization of the 
endogenous cannabinoid system in terms of its components and numerous basic 
physiologic functions. Cannabinoid1 (CB1) receptors are present in nervous system areas 
involved in modulating nociception and evidence supports a role of the endocannabinoids 
in pain modulation. Cannabinoids have antinociceptive mechanisms different from that of 
other drugs currently in use, which thus opens a new line of promising treatment to 
mitigate pain that fails to respond to the pharmacologic treatments available, especially for 
neuropathic and inflammatory pains (Manzanares et al. 2006).  
Cannabis extracts and synthetic cannabinoids are still widely considered illegal substances. 
The Cannabis sativa plant has been exploited for medicinal, agricultural and spiritual 
purposes in diverse cultures over thousands of years. Cannabis has been used recreationally 
for its psychotropic properties, while effects such as stimulation of appetite, analgesia and 
anti-emesis have lead to the medicinal application of cannabis. Indeed, reports of medicinal 
efficacy of cannabis can been traced back as far as 2700 BC, and even at that time reports 
also suggested a neuroprotective effect of the cultivar (Scotter et al.).  
Preclinical and clinical studies have suggested that they may result useful to treat diverse 
diseases, including those related with acute or chronic pain. The discovery of cannabinoid 
receptors, their endogenous ligands, and the machinery for the synthesis, transport, and 
degradation of these retrograde messengers, has equipped us with neurochemical tools for 
novel drug design. Agonist-activated cannabinoid receptors, modulate nociceptive 
thresholds, inhibit release of pro-inflammatory molecules, and display synergistic effects 
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with other systems that influence analgesia, especially the endogenous opioid system. 
Cannabinoid receptor agonists have shown therapeutic value against inflammatory and 
neuropathic pains, conditions that are often refractory to therapy. Although the 
psychoactive effects of these substances have limited clinical progress to study cannabinoid 
actions in pain mechanisms, preclinical research is progressing rapidly.  
There has been anecdotal and preliminary scientific evidence of cannabis affording 
symptomatic relief in diverse neurodegenerative disorders. These include multiple sclerosis, 
Huntington’s, Parkinson’s and Alzheimer’s diseases, and amyotrophic lateral sclerosis. This 
evidence implied that hypofunction or dysregulation of the endocannabinoid system may 
be responsible for some of the symptomatology of these diseases.  
In Huntington’s disease, Alzheimer’s disease, as well as in ALS, pathologic changes in 
endocannabinoid levels and CB2 expression are induced by the inflammatory environment. 
CB1 activation has been shown to be effective in limiting cell death following excitotoxic 
lesions, while CB2 is involved in dampening inflammatory immune cell response to disease. 
These two targets may therefore work together to provide both neuroprotection to acute 
injury and immune suppression during more chronic responses (Scotter et al.).  
During the last two decades, a large number of research papers have demonstrated the 
efficacy of cannabinoids and modulators of the endocannabinoid system in suppressing 
neuropathic pain in animal models. Cannabinoids suppress hyperalgesia and allodynia (i.e. 
mechanical allodynia, mechanical hyperalgesia, thermal hyperalgesia and, where evaluated, 
cold allodynia), induced by diverse neuropathic pain states through CB1 and CB2-specific 
mechanisms (Rahn and Hohmann 2009). 
On the other hand, responses to cannabinoid (CB) receptor activation include opening of 
potassium channels, inhibition of calcium currents, and stimulation of various protein 
kinases (Deadwyler et al. 1995; Gomez del Pulgar et al. 2000; Galve-Roperh et al. 2002; 
Karanian et al. 2005b; Molina-Holgado et al. 2005; Karanian et al. 2007). Some of the many 
such signaling elements activated by endocannabinoids play important roles in neuronal 
maintenance (Bahr et al. 2006; Galve-Roperh et al. 2008). CB receptor transmission elicits 
modulatory effects on calcium channels, resulting in reduced neurotransmitter (e.g., GABA, 
glutamate) release (Hajos et al. 2000; Kreitzer and Regehr 2001; Wilson et al. 2001). One 
particular mitogen-activated protein kinase, extracellular signal-regulated kinase (ERK), is 
involved in cannabinergic signaling, as are focal adhesion kinase (FAK) and 
phosphatidylinositol 3′-kinase (PI3K). These signaling elements appear to play key roles in 
the neuroprotective nature of the endocannabinoid system, and the associated signaling 
pathways are disrupted by blocking CB receptor activation (Hwang et al.; Wallace et al. 
2003; Khaspekov et al. 2004; Karanian et al. 2005a; Karanian et al. 2005b).  
Together, these studies indicate that the neuroprotectant cannabinoids have antinociceptive 
properties.  
8. Neuroprotection and tolerance to the analgesic effect 
8.1 Opioid tolerance 
Many types of neuronal cells and brain nuclei have the property of changing, acutely or 
chronically, their regular behavior by the action of pharmacological agents, such as 
psychoactive drugs. Acute changes, those that cease in a short time, would not be important 
to the chronic altered behavior if the cell recovered its original drug-free state, but it is 
observed that some adaptation occurs that impairs such a recovery. In fact, the disturbed 
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cell under the influence of a drug tries to compensate for its acute effects by promoting 
changes in the opposite direction, transiently restoring its homeostasis. However, when the 
acute action of the drug is finished, the cell is imbalanced by its own reactive 
response(Sharma SK et al. 1975). As a consequence, the phenomenon of tolerance develops, 
that is, the need for an increased dose of the drug to produce the same effect (McQuay 1999). 
After tolerance is established, the withdrawal of the drug may produce physical or 
psychological symptoms opposed to the acute pharmacological actions of the drug itself. 
Opioid drugs are used clinically as unsurpassed analgesic agents but are also illegally 
abused on the street to induce a sense of well-being and euphoria. Tolerance to opioids, 
defined as a loss of effect following repeated treatments such that a higher dose is required 
for equivalent effect, limits the analgesic efficacy of these drugs  and contributes to the social 
problems surrounding recreational opioid abuse.  
In order to safely use morphine in clinic, we need to know how morphine tolerance and 
dependence are developed and what kinds of medicines could inhibit or prevent such 
mechanisms. In line with this, various approaches have been attempted to clarify the 
mechanisms underlying morphine tolerance and dependence. Here we summarize various 
proposed hypotheses and introduce our new approaches in this area. 
8.2 Mechanisms for acute morphine tolerance 
Prolonged and repeated exposures to opioid agonists reduce the responsiveness of G 
protein coupled opioid receptors. This reduction in receptor function is hypothesized to 
contribute to opioid tolerance, dependence, and addiction in humans (Nestler 1992). 
Substantial experimental evidence has divided this reduced function into separate but 
correlated receptor traffickings, 1) desensitization, 2) internalization, 3) 
sequestration/recycling, 4) down regulation (Law et al. 2000). The molecular events 
underlying opioid tolerance are currently discussed in relation to all these receptor 
trafficking mechanisms. According to current understanding, opioid receptors are 
desensitized on the cell surface through a phosphorylation process in the C-terminal (Afify 
et al. 1998) and/or third intracellular loop. On the other hand, receptor internalization or 
receptor disappearance from the cell surface, is now believed to contribute to resensitization 
through dephosphorylation during endosomal stages (Krueger et al. 1997; Zhang et al. 
1997). Down-regulation is a loss of receptor protein in cells through increased degradation 
or decreased synthesis of the receptor. Little is known, however, regarding the regulation of 
this mechanism and involvement in opioid tolerance. Thus, much research has been done on 
the molecular basis of events in receptor phosphorylation in the membranes and 
internalization. Recent studies revealed that cAMP-dependent protein kinase A (PKA) 
(Harada et al. 1990), protein kinase C (PKC) (Ueda et al. 1995), Ca2 +/calmodulin-dependent 
protein kinases (Koch et al. 1997), G protein-coupled receptor kinases (GRKs) (Zhang et al. 
1998), and mitogen-activated protein kinase (Polakiewicz et al. 1998) have roles in opioid 
receptor phosphorylation. PKC and GRK mechanisms are likely candidates for opioid 
desensitization and internalization (Ueda et al. 1995; Zhang et al. 1998).  
8.3 PKC hypothesis 
A number of reports have demonstrated that PKC is involved in the opioid tolerance or 
desensitization. Most of recent reports have demonstrated that PKC activators or inhibitors 
modulate opioid signaling in cells expressing opioid receptors. A series of reports have 
demonstrated the involvement of PKC in opioid tolerance by correlating both in vitro and in 
vivo studies.  
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8.4 Mechanisms for chronic morphine tolerance and dependence 
Clear difference between acute morphine tolerance and chronic one has not been 
demonstrated for a long time. In algogenic-induced nociceptive flexion (ANF) test in mice 
the peripheral morphine analgesia developed the acute tolerance by 4 h pretreatment with 
morphine (Ueda et al. 2001). However, the peripheral analgesia had no change in mice that 
were given morphine for 5 days, a treatment which caused a marked chronic tolerance to 
systemic morphine analgesia (Ueda and Inoue 1999). Thus, it is evident that acute morphine 
tolerance mediates distinct mechanisms from the chronic one, and chronic tolerance is likely 
mediated through a complicated neuronal network present in the central nervous system. 
8.5 cAMP hypothesis 
Since the report by Sharma et al. (1975), it has been accepted that cAMP may play a key role 
in the morphine tolerance and dependence. According to this so-called cAMP hypothesis, a 
morphine-induced decrease in cAMP production is getting disappeared during long-period 
exposure to morphine (Sharma SK et al. 1975). As the naloxone application causes an abrupt 
increase in cAMP production, some unidentified mechanisms are supposed to mediate an 
increase in cAMP production through specific gene expressions during chronic morphine 
treatment. A candidate could be a cAMP-responsive element binding protein (CREB), which 
is involved in the gene expression of adenylyl cyclase. In vivo study using knockout mice 
demonstrates that CREB plays roles in the development of morphine dependence 
(Maldonado et al. 1996). Although several compounds possessing the antagonistic activity 
are reported to inhibit morphine tolerance and dependence, they have serious side effects at 
the same time (Trujillo and Akil 1991; Mao et al. 1992; Trujillo 1995; Mao 1999; Habibi-Asl 
and Hassanzadeh 2004; Habibi-Asl 2005; Asl et al. 2008). 
8.6 Anti-opioid hypothesis 
In addition to mechanisms at the single cellular level, the plasticity through neuronal 
networks would be involved in the development of morphine tolerance and dependence, as 
above-mentioned. One of approaches to cut in the mechanisms is based on the view that 
enhanced anti-opioid neuronal activity during chronic morphine treatments might suppress 
the acute morphine actions. The candidates include cholecystokinin (Mitchell et al. 2000 ), 
neuropeptide FF (Lake et al. 1992), nociceptin (Ueda et al. 2000) and glutamate, as an 
NMDA receptor ligand (Ueda et al. 2000; Mao and Mayer 2001). Among them the nociceptin 
(N/OFQ) system has been extensively characterized to be involved in the development of 
morphine tolerance and dependence. NMDA receptor has been long supposed to play 
important roles in the development of morphine tolerance and dependence (Trujillo and 
Akil 1991). Although several compounds possessing the antagonistic activity are reported to 
inhibit morphine tolerance and dependence, they have serious side effects at the same time 
(Trujillo and Akil 1991; Mao et al. 1992; Trujillo 1995; Mao 1999; Habibi-Asl and 
Hassanzadeh 2004; Habibi-Asl 2005; Asl et al. 2008).  
8.7 Apoptosis hypothesis 
Apoptosis, or programmed cell death, is an active process of normal cell death during 
development and also occurs as a consequence of the cytotoxic effect of various neurotoxins 
(e.g., MPTP/MPP+, MDMA, ethanol and cocaine) (Sastry and Rao 2000). Among the drugs of 
abuse, cocaine has been shown to cause a direct cytotoxic effect on the foetal rat heart, and to 
induce apoptosis in foetal rat myocardial cells in a dose-dependent manner (Xiao et al. 2000). 
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The induction of apoptosis in neurons has been demonstrated to share the same basic 
mechanisms with all other cell types (Sastry and Rao 2000). In vitro studies also indicate that 
exposure to μ- and/or κ-opioid receptor agonists of neuronal cultures from embryonic chick 
brain (Goswami et al. 1998) and specific cell lines (Dawson et al. 1997; Singhal et al. 1998; 
Singhal et al. 1999) increases their vulnerability to death by apoptotic mechanisms. The 
molecular mechanisms of apoptosis (i.e., the detailed cascade of events from the cell surface to 
final changes in the nucleus) have not been established yet, but various key proteins are 
involved in the regulation of programmed cell death (Sastry and Rao 2000). Some members of 
the Bcl-2 family of proteins, such as Bcl-2 and Bcl-xL, suppresses apoptosis, while the 
expression of other, such as the homologues Bax and Bak, are pro-apoptotic (Adams and Cory 
1998). Specifically, the Bcl-2 oncoprotein, localized mainly to the mitochondrial membranes, 
has been shown to play an important role in protecting neurons from apoptotic cell death 
(Hockenbery et al. 1990), probably by preventing the release of cytochrome c (induced by Bax) 
and the subsequent activation of specific proteases termed caspases, the proteolytic enzymes 
which are crucial for the execution of nuclear fragmentation and apoptosis (Adams and Cory 
1998; Sastry and Rao 2000). In fact, Bax mRNA and Bax protein are increased in the substantia 
nigra of MPTP-treated mice (degeneration of dopamine neurons by apoptosis) (Hassouna et al. 
1996), and the release of cytochrome c from the mitochondria and the subsequent activation of 
caspases-3/9 was shown to play a key role in cocaine-induced apoptosis in foetal rat 
myocardial cells (Xiao et al. 2000). The results of our studies demonstrated that chronic 
morphine administration in rat, induced apoptosis; decrease in Bcl-2 and increase in caspase3 
activity in both cerebral cortex and lumbar spinal cord in rat (Hassanzadeh et al.). Another key 
element involved in the regulation of apoptosis is the Fas glycoprotein (also known as CD95 or 
Apo1), a cell surface receptor that belongs to the tumor necrosis factor receptor family (death 
receptors) and that is expressed abundantly in various tissues (Nagata 1999). In contrast to Bcl-
2 mitochondrial protein, the Fas receptor triggers cell apoptosis when it binds to its ligand, Fas, 
and Fas-mediated death bypasses the usual long sequence of signaling enzymes and 
immediately activates a pre-existing caspase cascade (Nagata 1999). In the context of the 
induction of aberrant apoptosis in opioid addiction, it was of great interest the in vitro study 
demonstrating the ability of morphine to increase, through a naloxone-sensitive mechanism, 
the expression (mRNA) of the pro-apoptotic receptor Fas in mouse splenocytes and in human 
blood lymphocytes (Yin et al. 1999). A relevant consequence of the morphine-induced 
potentiation of apoptosis in lymphocytes (Singhal et al. 1999; Yin et al. 1999) is the reduction of 
the immune response (and the increase in recurrent infections) observed in heroin addicts 
(Govitrapong et al. 1998). 
On the other hand, over a decade, the NMDA receptor (NMDAR), a subgroup of glutamate 
receptors, has been implicated in the development of opioid tolerance (Trujillo and Akil 1991; 
Mao et al. 1994). Activation of NMDARs can lead to neurotoxicity under many circumstances 
(Rothman and Olney 1986; Moncada et al. 1992; Catania et al. 1993) For instance, peripheral 
nerve injury has been shown to activate spinal cord NMDARs, which results in not only 
intractable neuropathic pain but also neuronal cell death by means of apoptosis (Mao et al. 
1997; Whiteside and Munglani 2001). Furthermore, cross talk between the cellular mechanisms 
of opioid tolerance and neuropathic pain has been proposed, suggesting that a common 
cellular mechanism may be involved in both neuropathic pain and opioid tolerance (Mayer et 
al. 1999). Thus, it is possible that the cellular process leading to the development of opioid 
tolerance may also cause neurotoxic changes in response to prolonged opioid administration. 
More recently, we examined the hypothesis that neurotoxicity in the form of apoptotic cell 
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death would be induced in association with the development of morphine tolerance. In 
confirmation of Mao et al. findings, we demonstrated that chronic opioid injection leads to 
apoptosis in the CNS which was in association with the development of tolerance to the 
analgesic effect (Habibi-Asl et al. 2009a).  Figure1 shows the possible mechanisms of opioid-
induced neuronal apoptosis and its association with opioid tolerance. 
 
 
Fig. 1. Schematic diagram illustrating the possible mechanisms of opioid-induced neuronal 
apoptosis and tolerance. The results of before studies suggest that chronic opioid 
administration may induce NMDAR, microglia, FAAD/P53,… activation resulting in 
intracellular positive apoptosis regulators induction. The resultant apoptosis contributes to 
the cellular mechanism of opioid tolerance. NMDA: N-Methyl-D-Aspartate, NO: Nitric 
Oxide, AIF: Apoptosis-Inducing Factor, FADD: Fas-Associated Death Domain,  
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Opioid tolerance manifests as a loss of agonist potency and as a shift of the dose-response 
curve to the right. During the past decades, many studies have focused on excitatory amino 
acid receptors to investigate the role which they play in the development of tolerance to the 
antinociceptive action of opiates. This idea was suggested by Trujillo and Akil who reported 
that the NMDA receptor antagonist, MK801 (dizocilpine), inhibited the development of 
tolerance to the antinociceptive effect of morphine and morphine physical dependence 
(Trujillo and Akil 1991). 
Using behavioral studies, we and others have shown that a variety of NMDA receptor 
antagonists have the ability to inhibit the development of opiate tolerance and dependence 
(Trujillo and Akil 1991; Trujillo 1995; Habibi-Asl and Hassanzadeh 2004; Asl et al. 2008; 
Habibi-Asl et al. 2009b). There are also several lines of evidence which suggest that 
activation of NMDARs leads to removing the magnesium blockade (Begon et al. 2001) in the 
calcium channel and toxic calcium influx, which activates numerous enzymes, including 
neuronal nitric oxide (NO) synthase (NOS). In our unpublished data we observed that nitric 
oxide donors such as nitroglycerin or nicorandil increased the tolerance to the analgesic 
effect of morphine. On the other hand the nitric oxide synthase inhibitor, N-Nitro-L-
Arginine Methyl Ester (LNAME) could prevent the tolerance.  It has been demonstrated that 
Magnesium (Mg)-deficient rats develop a mechanical hyperalgesia which is reversed by a 
N-Methyl-D-Aspartate (NMDA) receptor antagonist (Begon et al. 2001). Our study in 
agreement with those studies showed that systemic administration of magnesium sulfate 
could attenuate morphine tolerance to the analgesic effect (Habibi-Asl 2005; Habibi-Asl et al. 
2009b). Also we showed that selenium with similar mechanism appeared to have a weaker 
effect than magnesium (Charkhpour M et al. 2009).   
Our recently published finding, indicated that riluzole (2- amino-6-[trifluoromethoxy] 
benzothiazole), an antiglutamatergic agent, decreases the development of tolerance, shifting 
the first day of established tolerance from the 8th day in the control group to the 13th day 
(Habibi-Asl et al. 2009a). Riluzole interferes with responses mediated by excitatory amino 
acids, even though it does not interact with any known binding sites on the NMDA, kainate 
or AMPA glutamate receptors (Debono et al. 1993). The neuroprotective effect of riluzole, 
which has been shown both in vivo and in vitro, is believed to be beneficial in various 
neurodegenerative diseases and amelioration of trauma and stroke (Doble 1999; Albo et al. 
2004).  
The results indicated that there was a significant shift to the right in the dose-response curve 
as well as an increase in the antinociceptive 50% effective dose (ED50) of morphine for 
animals who received morphine also compared with those that received morphine and 
riluzole. On the other hand, co-administration of riluzole delayed the onset of morphine-
induced apoptosis and significantly decreased the average number of TUNEL-positive cells 
(p < 0.01). This finding is in line with our recent results concerning the lumbar region of the 
spinal cord (Hassanzadeh et al.). In addition, we found that the group that received 
morphine and riluzole for 13 days had developed tolerance; they showed an increase in the 
number of apoptotic cells, as under control conditions. This result indicates that after the 
completion of tolerance in both the control and the treated groups, apoptosis had already 
developed. Previous studies have indicated that certain addictive drugs, such as morphine, 
could induce apoptosis in cultured neuronal cell lines  as well as human cells (Singhal et al. 
1998; Singhal et al. 1999). More recently, it has been shown that in vivo neuronal apoptosis 
occurs in the rat’s spinal cord dorsal horn after chronic morphine treatment that was 
associated with the expression of activated caspase- 3 and the involvement of mitogen-
www.intechopen.com
 
Pain Management – Current Issues and Opinions 
 
92
activated protein kinase (MAPK) (Mao et al. 2002), suggesting that chronic morphine may 
lead to changes within the central nervous system. 
Our more recent studies demonstrated that prolonged morphine administration induces up-
regulation of proapoptotic elements such as caspase-3 and down regulation of the anti-
apoptotic factors Bcl-2 and HSP70 in the rat cerebral cortex and spinal cord (Hassanzadeh et 
al.; Hassanzadeh et al.; Tikka and Koistinaho 2001; Gabra et al. 2005; Hassanzadeh K et al. 
2011). Importantly, up-regulation of caspase-3 and Bax was inhibited when morphine was 
co-administered with the noncompetitive NMDAR antagonist MK-801, thereby supporting 
a link between NMDAR activation and intracellular changes in caspase-3 and Bax in 
response to prolonged morphine administration (Jordan et al. 2007). 
Interestingly, our results demonstrated that neuroprotective agents such as serotonin1A 
receptor agonist, minocycline (Habibi-Asl 2009; Habibi-Asl et al. 2009a), selegiline,… could 
prevent morphine induced tolerance and apoptosis. The stimulation of serotonin1A (5HT1A) 
receptors induces a variable level of neuroprotection in different animal models of central 
nervous system injury such as ischemia, (Prehn et al. 1993; Semkova et al. 1998; Schaper et 
al. 2000; Kukley et al. 2001; Torup et al. 2000) N-methyl-D-aspartate (NMDA) excitotoxicity, 
(Oosterink et al. 1998; Oosterink et al. 2003) acute subdural hematoma, (Alessandri et al. 
1999) and traumatic brain injury (Kline et al. 2001). Furthermore, in vitro evidence indicates 
that 5HT1A agonists are able to protect neurons from apoptosis induced by staurosporine 
(Suchanek et al. 1998), glutamate (Semkova et al. 1998), or serum deprivation (Ahlemeyer 
and Krieglstein 1997; Ahlemeyer et al. 1999). There are different hypotheses on the 
mechanisms involved in 5HT1A-mediated neuroprotection, including neuronal membrane 
hyperpolarization that reduces excitability,(Ahlemeyer and Krieglstein 1997; Krüger et al. 
1999), reduced glutamate release, (Mauler et al. 2001) and blockade of voltage-sensitive Na 
channels (Melena et al. 2000). 
Other neuroprotective mechanisms have also been proposed for 5HT1A agonists such as 
stimulation of the anti-apoptotic proto-oncogene B-cell lymphoma protein 2 (BCL-2) 
expression through the mitogen-activated protein kinase (MAPK/ERK) signaling pathway 
(Kukley et al. 2001) and suppression of the proapoptotic protein caspase-3 in a MAPK- and 
protein kinase C alfa-dependent manner (Adayev et al. 2003). 
More recently we examined the effect of 8-OH-DPAT, a specific 5-HT1A receptor agonist, on 
morphine induced tolerance to an analgesic effect in rat. We found that Intra-dorsal raphe 
nucleus (DRN) administration of the 5-HT1A receptor agonist, 8-OH-DPAT, prevented 
morphine-induced apoptosis after tolerance to the analgesic effect. On the other hand, the 
total analgesic effect of morphine significantly increased in animals treated with morphine 
and 8-OH-DPAT in comparison with the control group. In addition, the results indicated 
that administration of both 5HT1 agonist (8-OH-DPAT) and antagonist (NAN-190) together 
with morphine prevent the antiapoptotic activity of the 5HT1A agonist. This means that 
after antagonizing the 5HT1A receptor, the apoptosis process has already developed. 
Another mechanism contributes to the morphine tolerance is microglial activation. Studies 
showed that NMDA-induced neuronal death involved proliferation and activation of 
microglial cells and that neuroprotective agents such as minocycline completely prevented 
NMDA toxicity and the preceding activation and proliferation of microglial cells. These 
results support the notion that microglial activation contributes to excitotoxic neuronal 
death, which can be inhibited by anti- inflammatory compounds, such as minocycline 
(Tikka and Koistinaho 2001). The mechanism underlying the role of glial cells in the effects 
of morphine on naive mice is unclear. It is possible that morphine acts directly on microglia, 
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triggering alterations in their morphology, metabolism, and function (Watkins et al. 2005). 
Mika et al. concluded that the effect of minocycline on morphine tolerance is related to 
microglia. Their results provide evidence that systemic administration of minocycline in 
mice influences morphine’s effectiveness and delays the development of morphine tolerance 
by attenuating microglial activation and its markers (Mika et al. 2009). 
In summary, we believe that adding the neuroprotective agents to analgesic drugs specially 
opioids, increase the analgesic effect and prevents the hyperalgesia and tolerance to their 
analgesic effects. 
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